Optimer Pharmaceuticals' fidaxomicin was as effective as standard therapy Vancocin in treating Clostridium difficile infection in a second Phase III trial, the company announced. The antibiotic also demonstrated a higher cure rate without recurrence and a lower recurrence rate compared with Vancocin in the four-week treatment period, according to the study.

Full Story:

Related Summaries